Developing life-changing medicines for extremely preterm infants and patients with rare autoimmune diseases has earned Oak Hill Bio a fresh infusion of capital. The clinical-stage biotech company has successfully closed its Series A funding round, raising $32.5M to advance its specialized pipeline.
The investment round saw participation from a notable group of backers, including Balyasny Asset Management L.P., Janus Henderson Investors, venBio, and KCap Biotechnology Fund LP, underscoring confidence in Oak Hill Bio's mission.














